Sernova Corp. announced that the Board of Directors has appointed Jonathan Rigby, who previously joined as a Director in May, as Executive Chairman effective immediately. Brett Whalen, who was previously Chairman, has resigned from the Board. These changes continue carefully curated management and Board transitions aimed at positioning Sernova to enter the next phase of the Company's growth and evolution. As Executive Chairman Mr. Rigby will focus on partnering with company leadership on capital markets efforts for Sernova as well as leadership of the Board. Cynthia Pussinen, the Company's
Chief Executive Officer, will continue in her role as originally defined managing Sernova's day to day business strategy and operations; she will continue to report to the Board. Mr. Rigby has held several CEO roles and currently serves on the Board of Directors of cancer therapy company Oncolytics Biotech Inc. and IM Therapeutics and was formerly on the board of Xeris Pharmaceuticals. Mr. Rigby holds a degree in Biological Sciences from the University of Sheffield, UK, and has a Master of Business Administration degree from the University of Portsmouth, UK.